External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EAHAD 2025

-
Coming soon
05:30 PM
Duration 1hr Milan, Italy
Joint health and physical activity in people with haemophilia A without factor VIII inhibitors before switching to emicizumab prophylaxis: BEYOND ABR study interim analysis
Castaman G, Di Minno MND, Kruse-Jarres R, Stephensen D, Lobet S, Robson S, Brocchieri C, Jimenez-Yuste V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1hr Milan, Italy
Health-related quality of life (HRQoL), physical activity (PA) and joint health in people with severe haemophilia A (PwSHA) and a bleeding phenotype receiving emicizumab – results from the HemiNorth 2 study
Astermark J, Ranta S, Westesson L M, Hoffman M, Quere S, Castro Sanchez A Y, Robson S, Czirok T, Lassila R, Holme P A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:30 AM
Duration 75mins Milan, Italy
Moving beyond limits: Exploring evidence to support active lifestyles for people with haemophilia A
Dr Giancarlo Castaman, Greig Blamey, Paula Loughnane

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:48 AM
Duration 8mins Hall 4
Pharmacodynamics (PD) and pharmacokinetics (PK) of dirloctocogene samoparvovec in people with severe to moderately severe hemophilia A (HA)
Lindsey George

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar